Navigation Links
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
Date:4/22/2010

NEW YORK, LONDON and HAMILTON, Bermuda, April 22 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the initiation of a Phase I/II pediatric dose tolerance trial to test their investigational new drug XERECEPT® in pediatric patients suffering from primary, recurrent or metastatic brain tumors.

Celtic Pharma's objective for this trial is to rapidly demonstrate the tolerability to increasing doses of XERECEPT® in pediatric patients.  Upon identification of the maximum tolerated dose, the study will continue to investigate the clinical benefits of XERECEPT® in this population, particularly with regard to reduction of dexamethasone dosing requirements and concomitant clinical benefit to the patients.  Dr. Stewart Goldman, medical director of the Neuro-Oncology unit at Northwestern University's Feinberg School of Medicine and the study's Principal Investigator commented, "I am excited to be working on this very important trial.  The effects of dexamethasone dosing on these children who have brain tumors is heart wrenching and I look forward to working with Celtic Pharma in the testing of XERECEPT® in these patients."

Stephen Evans-Freke, co-Managing General Partner of Celtic Pharma further commented, "The current standards of care and prognosis for pediatric patients with brain tumors is very poor and we believe that XERECEPT® may provide a welcome and needed treatment for these children, in whom the effects of high-dose steroids are so devastating.  We have been in close contact with leading pediatric neuro-oncologists and look forward to the completion of this trial. This study is an important el
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
4. Celator(R) Pharmaceuticals Presents New Data on Two Nano-Scale Delivery Platforms at the American Association for Cancer Research
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
7. Who Is The Next-Generation Pharmacist(TM)?
8. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
9. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
10. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
11. NCPA Commends Pharmacy Provisions in House-Passed Health Care Reform Bill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (NASDAQ: CYTR ), a biopharmaceutical research and development ... the three months ended June 30, 2015, and also ... for its clinical development programs. "The second ... Enrollment in our ongoing pivotal global Phase 3 clinical ... on track to be completed in the first quarter ...
(Date:8/3/2015)... , Aug. 3, 2015 Merrimack Pharmaceuticals, ... will host its Second Quarter 2015 Investor Conference Call ...    The call will cover an update ... second quarter 2015 financials. A press release detailing the ... issued the afternoon of Monday, August 10. Investors and ...
(Date:8/3/2015)...  Celsion Corporation (NASDAQ: CLSN ) announced ... call to discuss its second quarter 2015 financial ... programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation ... TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery ... 2015. To participate in the call, interested parties ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... EAU study conducted with University of Pennsylvania shows ... different approaches,are being used to increase milk production ... at the University of Pennsylvania School of,Veterinary Medicine ... technology created by EAU Technologies, has the potential ...
... study to commence late this year, ... (ASX:,CYT) has selected CYT387, a selective and ... treat myeloproliferative disorders (MPDs). This,follows extensive laboratory ... in an in-vivo model of myeloproliferative,disease., ...
Cached Medicine Technology:Increasing Dairy Milk Production with Electrolyzed Drinking Water 2Increasing Dairy Milk Production with Electrolyzed Drinking Water 3Increasing Dairy Milk Production with Electrolyzed Drinking Water 4Increasing Dairy Milk Production with Electrolyzed Drinking Water 5Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders 2Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders 3
(Date:8/4/2015)... Louis, MO (PRWEB) , ... August 04, 2015 ... ... attorneys handling national talcum powder lawsuits filed against Johnson & Johnson report that ... Talcum powder lawyers provide regular news updates and cancer warning information ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... digital press at its Denver facility that will usher in a new standard ... Lightning Labels more effectively meet its twin objectives of quality and ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... for executives and technology professionals in healthcare and technology markets, today announced significant ... Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related numbers ...
(Date:8/3/2015)... ... August 04, 2015 , ... ... an extensive line up of live courses for the month of August. , ... courses individually or by purchasing a Physical Therapy Flex package. Flex packages ...
(Date:8/3/2015)... ... 03, 2015 , ... Zeiter’s Septic now performs septic installations ... and operated business, Zeiter’s Septic has been serving the community for over 20 ... because of their continued training and perseverance to provide their customers with new ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3
... San Francisco-to-Los Angeles ride May 31SAN FRANCISCO and LOS ... 41 states and 14 nations will stream out of ... Angeles as participants in the colorful and emotional AIDS/LifeCycle, ... expected to raise more than $10 million to support ...
... , , THURSDAY, May 28 (HealthDay News) -- A total ... motion in arthritic or deformed ankles has been approved ... Scandinavian Total Ankle Replacement (STAR) system is the first ... a surface of flexible plastic (polyethylene). , Total ankle ...
... PregnancyWHITE PLAINS, N.Y., May 28 Starting pregnancy at ... pregnancy is critical to giving a baby a healthy ... in response to new guidelines from the Institute of ... for the amount of weight a woman should gain ...
... in Independent CategoryNEW YORK, May 28 Prix ... development, has added a new recognition category to its 2009 ... Prix Galien USA are now being accepted at ... 1, 2009. For the first time, the Prix Galien USA ...
... Covers High-throughput, Anchorage-independent Assay for Screening Compounds for ... Falcon Genomics, Inc. announced today that it has ... the Company,s Cancer BioChip System (CBCS) for the ... a high-throughput in vitro setting with ...
... bacteria in the small intestine are both associated with ... in a new study in the June issue of ... & Sons on behalf of the American Association for ... also available online at Wiley Interscience ( www.interscience.wiley.com ). ...
Cached Medicine News:Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 2Health News:AIDS/LifeCycle 8 to Raise $10+ Million to Fight AIDS 3Health News:Ankle Replacement System Lets Feet Move 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 2Health News:New Guidelines to Fight Obesity in Pregnancy Issued 3Health News:Prix Galien USA Now Accepting Nominations for Premiere Biopharmaceutical Industry Award 2Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2Health News:Intestinal bacteria associated with non-alcoholic fatty liver disease 2
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 25 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: